Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing PactBenzinga • 04/19/21
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive DisorderGlobeNewsWire • 03/22/21
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CRGlobeNewsWire • 03/19/21
Tonix Pharma's COVID-19 Vaccine Candidate Shows Encouraging Efficacy In Animal StudiesBenzinga • 03/17/21
Tonix Pharmaceuticals Reports Positive COVID-19 Vaccine Efficacy Results in Non-Human Primates Vaccinated with TNX-1800 and Challenged with Live SARS-CoV-2GlobeNewsWire • 03/17/21
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsGlobeNewsWire • 03/15/21
Tonix Pharma Shares Rally After In-Licensing Of Technology For A Rare Genetic Eating DisorderBenzinga • 02/11/21
Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)GlobeNewsWire • 02/11/21
Tonix Pharmaceuticals to Participate in BIO CEO & Investor Digital ConferenceGlobeNewsWire • 02/10/21
Tonix Pharmaceuticals Holdings Corp. Closes $70M Common Stock Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 02/09/21
Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 02/08/21
